Drs Simeone and Fakih discuss the main objective and design of the observational BASECAMP-1 study and how it functions alongside the EVEREST-1 study, which is evaluating the autologous CAR T-cell therapy A2B530 in patients with CEA-expressing solid tumors that have lost HLA-A 02 expression.
Looking to replicate the impressive findings with CAR T-cell therapies observed in patients with hematologic malignancies, investigators have initiated the BASECAMP-1 trial, with the hope of identifying patients with advanced solid tumors who will be suitable candidates for treatment in a subsequent trial evaluating the investigational agent A2B530.
What started as lower abdominal pains in January 2021 that would strike suddenly, like labor pains, eventually escalated to unintended weight loss, loss of appetite, blood in the stool and frequent vomiting for Melissa Ursini, 37, of Santa Clarita.